BKM120 + Trastuzumab + Paclitaxel + BKM120 Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
HER2-positive Newly Diagnosed, Primary Breast Cancer
Conditions
HER2-positive Newly Diagnosed, Primary Breast Cancer
Trial Timeline
Sep 3, 2013 → Feb 18, 2015
NCT ID
NCT01816594About BKM120 + Trastuzumab + Paclitaxel + BKM120 Placebo
BKM120 + Trastuzumab + Paclitaxel + BKM120 Placebo is a phase 2 stage product being developed by Novartis for HER2-positive Newly Diagnosed, Primary Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01816594. Target conditions include HER2-positive Newly Diagnosed, Primary Breast Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01816594 | Phase 2 | Completed |
Competing Products
20 competing products in HER2-positive Newly Diagnosed, Primary Breast Cancer